


Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

November 2025

The logo for PHARMAC (Te Pātaka Whaioranga) is centered within a white circle. The background of the entire page is a light gray, featuring a large, stylized graphic of white and gray wavy lines that resemble ocean waves or a traditional Māori koru pattern. The text 'PHARMAC' is in a large, bold, sans-serif font, and 'TE PĀTAKA WHAIORANGA' is in a smaller, all-caps, sans-serif font below it.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 November 2025 3

Section H changes to Part II 5

Index 8

Summary of decisions

EFFECTIVE 1 NOVEMBER 2025

- Amphotericin B (Amphotericin Liposomal SUN) inj (liposomal) 50 mg vial – new listing and addition of PSS
- Amphotericin B (AmBisome) inj (liposomal) 50 mg vial, 1 inj and 10 inj pack – to be delisted 1 April 2026
- Coal tar (Midwest) soln BP, 200 ml – price increase
- Compound hydroxybenzoate (Midwest) soln, 100 ml – price increase
- Enteral feed 1.5 kcal/ml (Ensure Plus HN) liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, 250 ml can – to be delisted 1 March 2026
- Ethinyloestradiol with levonorgestrel tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets (Lo-Oralcon 20 ED) and tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets (Oralcon 30 ED) – price increase and addition of PSS
- Glycerin with sodium saccharin (Ora-Sweet SF) suspension, 473 ml – price increase
- Glycerin with sucrose (Ora-Sweet) suspension, 473 ml – price increase
- Heparin sodium (Pfizer) inj 5,000 iu per ml, 5 ml ampoule – new listing and addition of PSS
- Heparin sodium (Heparin Sodium Panpharma) inj 5,000 iu per ml, 5 ml vial – to be delisted 1 May 2026
- Imiquimod (Padagis) crm 5%, 250 mg sachet – new listing
- Lenalidomide (Viatrix) (Lenalidomide Viatrix) cap 10 mg – Pharmacode 2673533 to be delisted 1 January 2026
- Lidocaine [lignocaine] hydrochloride (Xylocaine Viscous) oral (gel) soln 2%, 200 ml – new listing and addition of PSS
- Lidocaine [lignocaine] hydrochloride (Mucosoothe) oral (gel) soln 2%, 200 ml – to be delisted 1 April 2026
- Methyl hydroxybenzoate (Midwest) powder, 25 g – price increase
- Methylcellulose (Ora-Plus) suspension, 473 ml – price increase
- Methylcellulose (Midwest) Powder, 100 g – price increase and to be delisted 1 February 2028
- Methylcellulose with glycerin and sodium saccharin (Ora-Blend SF) suspension, 473 ml – price increase
- Methylcellulose with glycerin and sucrose (Ora-Blend) suspension, 473 ml – price increase
- Metoclopramide hydrochloride (Medsurge) inj 5 mg per ml, 2 ml ampoule – new listing and addition of PSS
- Metoclopramide hydrochloride (Baxter) inj 5 mg per ml, 2 ml ampoule – to be delisted 1 April 2026

Summary of decisions – effective 1 November 2025 (continued)

- Nortriptyline hydrochloride (Norpress) tab 10 mg and 25 mg – to be delisted 1 March 2026
- Olanzapine (Zypine) tab 10 mg – new listing
- Omeprazole (Midwest) powder for oral liq, 5 g – price increase
- Oral feed 1.5 kcal/ml (Ensure Plus (Vanilla)) liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, 237 ml can – to be delisted 1 July 2026
- Paediatric oral feed 1 kcal/ml (Pediasure (vanilla)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 250 ml can – delisted 1 November 2025
- Risperidone (Risperon) oral liq 1 mg per ml, 100 ml – new listing
- Sertraline (Setrona) tab 50 mg and 100 mg – price increase and addition of PSS
- Sodium bicarbonate (Midwest) powder BP, 500 g – price increase
- Syrup (Midwest) liq (pharmaceutical grade), 500 ml – price increase
- Ticagrelor (Ticagrelor Sandoz) tab 90 mg – amended restriction criteria

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 November 2025

ALIMENTARY TRACT AND METABOLISM

8	OMEPRAZOLE († price) Powder for oral liq	52.00	5 g	Midwest
---	---	-------	-----	---------

BLOOD AND BLOOD FORMING ORGANS

37	HEPARIN SODIUM (new listing and addition of PSS) Inj 5,000 iu per ml, 5 ml ampoule – 5% DV May-26 to 2028	406.15	50	Pfizer
37	HEPARIN SODIUM (delisting) Inj 5,000 iu per ml, 5 ml vial.....	83.00	10	Heparin Sodium Panpharma
Note – Heparin Sodium Panpharma inj 5,000 iu per ml, 5 ml vial to be delisted from 1 May 2026.				
38	TICAGRELOR (amended restriction criteria – new criteria shown only) → Tab 90 mg – 5% DV Dec-24 to 2027	20.35	56	Ticagrelor Sandoz
Restricted Initiation – acute minor stroke or high-risk transient ischemic attack (TIA)* All of the following: 1 Patient has been diagnosed with a minor stroke (NIHSS† score 3 or less), high-risk TIA (ABCD2 score 4 or more) or Crescendo TIA; and 2 Either: 2.1 Patient is expected to be a poor metaboliser of clopidogrel, with documented clinical rationale; or 2.2 Patient is allergic to clopidogrel**; and 3 Ticagrelor to be prescribed for a maximum of 21 days following minor stroke or TIA. Continuation – subsequent minor stroke or high-risk transient ischemic attack Re-assessment required after 1 month Patient has been diagnosed with a minor stroke (NIHSS score 3 or less) or high-risk transient ischemic attack (ABCD2 score 4 or more) or Crescendo TIA. Note: indications marked with * are unapproved indications. Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment. Note: NIHSS† National Institutes of Health Stroke Scale.				

DERMATOLOGICALS

72	IMIQUIMOD (new listing) Crn 5%, 250 mg sachet	21.72	24	Padagis
----	--	-------	----	---------

GENITO-URINARY SYSTEM

73	ETHINYLOESTRADIOL WITH LEVONORGESTREL († price and addition of PSS) Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – 5% DV Apr-26 to 2028	2.00	84	Lo-Oralcon 20 ED
	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – 5% DV Apr-26 to 2028	2.30	84	Oralcon 30 ED

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2025 (continued)

INFECTIONS

96	AMPHOTERICIN B (brand change and addition of PSS) → Inj (liposomal) 50 mg vial – 5% DV Apr-26 to 2028	125.00	1	Amphotericin Liposomal SUN
Note – AmBisome inj (liposomal) 50 mg vial, 1 inj and 10 inj pack to be delisted from 1 April 2026.				

NERVOUS SYSTEM

123	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (brand change and addition of PSS) Oral (gel) soln 2% – 5% DV Apr-26 to 2028	30.80	200 ml	Xylocaine Viscous
Note – Mucosoothe oral (gel) soln 2% to be delisted from 1 April 2026.				
128	NORTRIPTYLINE HYDROCHLORIDE (delisting) Tab 10 mg	2.46	100	Norpress
	Tab 25 mg	6.29	180	Norpress
Note – Norpress tab 10 mg and 25 mg to be delisted from 1 March 2026.				
128	SERTRALINE (↑ price and addition of PSS) Tab 50 mg – 5% DV Apr-26 to 2028	1.24	30	Setrona
	Tab 100 mg – 5% DV Apr-26 to 2028	2.00	30	Setrona
133	METOCLOPRAMIDE HYDROCHLORIDE (brand change and addition of PSS) Inj 5 mg per ml, 2 ml ampoule – 5% DV Apr-26 to 2028	5.48	10	Medsurge
Note – Baxter inj 5 mg per ml, 2 ml ampoule to be delisted from 1 April 2026.				
135	OLANZAPINE (new listing) Tab 10 mg – 5% DV Aug-24 to 2026	1.80	28	Zypine
135	RISPERIDONE (new listing) Oral liq 1 mg per ml – 5% DV Mar-24 to 2026	34.30	100 ml	Risperon

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

153	LENALIDOMIDE (VIATRIS) (delisting) → Cap 10 mg – 5% DV Feb-25 to 31 Jan 2028	50.30	21	Lenalidomide Viatris
Note – this delist applies to Pharmacode 2673533, to be delisted from 1 January 2026.				

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

289	COAL TAR (↑ price) Soln BP	46.00	200 ml	Midwest
289	COMPOUND HYDROXYBENZOATE (↑ price) Soln	36.00	100 ml	Midwest
290	GLYCERIN WITH SODIUM SACCHARIN (↑ price) Suspension	38.00	473 ml	Ora-Sweet SF
290	GLYCERIN WITH SUCROSE (↑ price) Suspension	38.00	473 ml	Ora-Sweet

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2025 (continued)

290	METHYL HYDROXYBENZOATE († price) Powder.....	11.00	25 g	Midwest
290	METHYLCELLULOSE († price) Suspension	38.00	473 ml	Ora-Plus
290	METHYLCELLULOSE († price and delisting) Powder..... Note – Midwest (brand only) powder to be delisted from 1 February 2028.	44.00	100 g	Midwest
290	METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN († price) Suspension	38.00	473 ml	Ora-Blend SF
290	METHYLCELLULOSE WITH GLYCERIN AND SUCROSE († price) Suspension	38.00	473 ml	Ora-Blend
290	SODIUM BICARBONATE († price) Powder BP	13.50	500 g	Midwest
291	SYRUP († price) Liq (pharmaceutical grade)	25.00	500 ml	Midwest

SPECIAL FOODS

306	PAEDIATRIC ORAL FEED 1 KCAL/ML (delisted) → Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 250 ml can.....	1.66	1	Pediasure (vanilla)
	Note – Pediasure (vanilla) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 250 ml can delisted 1 November 2025.			
308	ENTERAL FEED 1.5 KCAL/ML (delisting) → Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, 250 ml can.....	2.17	1	Ensure Plus HN
	Note – Ensure Plus HN liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, 250 ml can to be delisted from 1 March 2026.			
309	ORAL FEED 1.5 KCAL/ML (delisting) → Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, 237 ml can.....	1.65	1	Ensure Plus (Vanilla)
	Note – Ensure Plus (Vanilla) liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, 237 ml can to be delisted from 1 July 2026.			

Index

Pharmaceuticals and brands

A	
AMPHOTERICIN B	6
Amphotericin Liposomal SUN	6
C	
COAL TAR	6
COMPOUND HYDROXYBENZOATE	6
E	
Ensure Plus HN	7
Ensure Plus (Vanilla)	7
ENTERAL FEED 1.5 KCAL/ML	7
ETHINYLOESTRADIOL WITH LEVONORGESTREL	5
G	
GLYCERIN WITH SODIUM SACCHARIN	6
GLYCERIN WITH SUCROSE	6
H	
HEPARIN SODIUM	5
I	
IMIQUIMOD	5
L	
Lenalidomide Viatris	6
LENALIDOMIDE (VIATRIS)	6
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE	6
LIGNOCAINE	6
Lo-Oralcon 20 ED	5
M	
METHYLCELLULOSE	7
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN	7
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE	7
METHYL HYDROXYBENZOATE	7
METOCLOPRAMIDE HYDROCHLORIDE	6
N	
Norpress	6
NORTRIPTYLINE HYDROCHLORIDE	6
O	
OLANZAPINE	6
OMEPRAZOLE	5
Ora-Blend	7
Ora-Blend SF	7
Oralcon 30 ED	5
ORAL FEED 1.5 KCAL/ML	7
Ora-Plus	7
Ora-Sweet	6
Ora-Sweet SF	6
P	
Padagis	5
PAEDIATRIC ORAL FEED 1 KCAL/ML	7
Pediasure (vanilla)	7
R	
RISPERIDONE	6
Risperon	6
S	
SERTRALINE	6
Setrona	6
SODIUM BICARBONATE	7
SYRUP	7
T	
TICAGRELOR	5
Ticagrelor Sandoz	5
X	
Xylocaine Viscous	6
Z	
Zypine	6

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

